Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
Crossref DOI link: https://doi.org/10.1007/s12325-019-01202-2
Published Online: 2020-01-04
Published Print: 2020-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Guan, Haijing
Sheng, Yanan
Guo, Wanjie
Han, Sheng
Shi, Luwen
Text and Data Mining valid from 2020-01-04
Version of Record valid from 2020-01-04
Article History
Received: 12 December 2019
First Online: 4 January 2020